Dr. Oliver Dorigo
Claim this profileStanford University
Studies Ovarian Cancer
Studies Colorectal Cancer
4 reported clinical trials
5 drugs studied
Area of expertise
1Ovarian Cancer
BRCA2 negative
BRCA1 negative
HLA-A positive
2Colorectal Cancer
HLA-A positive
Stage III
Stage IV
Affiliated Hospitals
Clinical Trials Oliver Dorigo is currently running
B7-H3 CAR T Cells
for Ovarian Cancer
This is a single site, open label, Phase 1 study using a 3 + 3 dose escalation design in two cohorts of adults with recurrent, platinum-resistant ovarian tumors.
Recruiting1 award Phase 15 criteria
CRX100
for Solid Cancers
This clinical study is an open-label, Phase 1, dose-escalation study to determine the safety, tolerability, and efficacy of the drug product produced by Administering CRX100 alone and in combination with Pembrolizumab in advanced solid malignancies. Patients will be screened and evaluated to determine whether or not they meet stated inclusion criteria. Enrolled subjects will undergo leukapheresis to enable the ex vivo generation of CRX100. Patients with non-small cell lung cancer (NSCLC), ovarian cancer, colorectal cancer, hepatocellular carcinoma (HCC), malignant melanoma (excluding uveal melanoma), gastric cancer, triple negative breast cancer, and osteosarcoma. The study will start with monotherapy dose escalation followed by combination cohorts.
Recruiting1 award Phase 115 criteria
More about Oliver Dorigo
Clinical Trial Related4 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Oliver Dorigo has experience with
- CRX100
- B7-H3 CAR T Cells
- Alpelisib
- Olaparib
- A2B694
Breakdown of trials Oliver Dorigo has run
Ovarian Cancer
Colorectal Cancer
Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Oliver Dorigo specialize in?
Oliver Dorigo focuses on Ovarian Cancer and Colorectal Cancer. In particular, much of their work with Ovarian Cancer has involved BRCA2 negative patients, or patients who are BRCA1 negative.
Is Oliver Dorigo currently recruiting for clinical trials?
Yes, Oliver Dorigo is currently recruiting for 3 clinical trials in Stanford California. If you're interested in participating, you should apply.
Are there any treatments that Oliver Dorigo has studied deeply?
Yes, Oliver Dorigo has studied treatments such as CRX100, B7-H3 CAR T Cells, Alpelisib.
What is the best way to schedule an appointment with Oliver Dorigo?
Apply for one of the trials that Oliver Dorigo is conducting.
What is the office address of Oliver Dorigo?
The office of Oliver Dorigo is located at: Stanford University, Stanford, California 94305 United States. This is the address for their practice at the Stanford University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.